ASP2138 + Pembrolizumab + Oxaliplatin + Leucovorin + Fluorouracil + Ramucirumab + Paclitaxel + Irinotecan + Capecitabine
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Adenocarcinoma
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Trial Timeline
Jun 7, 2022 → May 31, 2027
NCT ID
NCT05365581About ASP2138 + Pembrolizumab + Oxaliplatin + Leucovorin + Fluorouracil + Ramucirumab + Paclitaxel + Irinotecan + Capecitabine
ASP2138 + Pembrolizumab + Oxaliplatin + Leucovorin + Fluorouracil + Ramucirumab + Paclitaxel + Irinotecan + Capecitabine is a phase 1 stage product being developed by Astellas Pharma for Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05365581. Target conditions include Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Adenocarcinoma were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05365581 | Phase 1 | Recruiting |
Competing Products
20 competing products in Gastric Adenocarcinoma